Avid Bioservices is investing approximately US$400 million to construct a new world-class cell and gene therapy development and manufacturing facility in California, USA.
The state-of-the-art CGT development and manufacturing facility, covers an area of 53,000 square feet.
This purpose-built facility is designed to support the entire spectrum of CGT production, from early-stage development to commercial manufacturing.
The facility boasts an expansive 6,000 square feet of dedicated laboratory space, fully equipped to support the quality control demands of both clinical and commercial CGT products.
The facility is equipped to handle a variety of culture types, including suspension culture batches of up to 3,000 litres and adherent cultures utilising fixed bed bioreactors. This versatility enables the production of a wide range of CGT products.
The manufacturing suites are designed with the latest technology for filling and capping, all performed under isolator conditions to ensure product integrity.
The new CGT facility produce life-saving therapies that will benefit patients worldwide.
Its anticipated opening in January 2024 marks a significant milestone in the advancement of cell and gene therapy.
Name Avid Bioservices
Type New Construction
Budget US$400 million
Year January 2024